Cognitive Deficits in Schizophrenia
Introduction of Schizophrenia
Over the past decades, significant advances in neuroscience have changed how schizophrenia is viewed and deepened our understanding of better treatments. Schizophrenia is a heterogeneous and chronic mental disorder characterized by various signs and symptoms and affects approximately 0.7% of the population worldwide. Most importantly, it is abundantly clear that schizophrenia is a brain disorder with strong genetic contributions. Highly heritable and complex polygenic traits characterize it.
The positive psychotic symptoms include hallucinations and delusions, and negative symptoms include motivation, social withdrawal, and apathy. The majority of patients also have a history of mild neuropsychological abnormalities, including disorganized thought processes, poor attention, distractibility, misperception, subdelusional features, and mild motor abnormalities during their childhood-findings indicating brain abnormalities predate the clinical diagnosis of schizophrenia. Once a diagnosis is made, patients have prescribed combinations of antipsychotic drugs that they take for their entire lives.
Cognitive Deficits in Schizophrenia
Cognitive impairment is an important cause of functional disability and related outcomes in schizophrenia. Cognitive deficit in schizophrenia is an original and core abnormality of the disease and reflects the pathophysiology. Cognitive deficits are present in all patients with schizophrenia. They are the most important predictor of the quality of life, ability to maintain social relationships, the likelihood of being employed, and long-term disability in these patients. The profile of cognitive deficits in schizophrenia includes many aspects: executive functioning, attention/vigilance, memory, reasoning, processing speed, language usage, and social cognition.
Fig.1 Severity and profile of cognitive impairment in schizophrenia. (Keefe, 2012)
Impairments in these domains are associated with alterations in the neural systems known to support these cognitive functions, including impairments in the function of the medial temporal lobes, the prefrontal cortex, and a range of neurotransmitter systems known to be important for intact cognitive function. The evidence points to dorsolateral prefrontal cortical abnormalities contributing to cognitive deficits of schizophrenia. Abnormalities in intrinsic, corticocortical, and cortico-subcortical circuitries contribute to the manifestation of cognitive deficits of schizophrenia. The goal of schizophrenia research is increasingly to understand the neural and genetic mechanisms of cognitive deficits. There is a dearth of effective treatments of schizophrenia; ameliorating cognitive deficits has thus become a priority of schizophrenia research.
Cognitive Deficits as Markers
In recent years, cognitive function in many areas of schizophrenia research has been examined, reflecting a growing understanding of schizophrenia from a neurocognitive perspective. Cognitive deficits are the best predictor of functional status across several outcome domains and patient characteristics. They are markers that can help identify genes that confer an increased risk of schizophrenia. Studies of emerging mechanisms for treating cognitive impairments suggest that the need to treat these impairments has become a priority for the field. It can be modifiable through both pharmacological and psychological intervention.
Services and Products at Creative Biolabs
Creative Biolabs has hugely experienced specialists working alongside our team, providing expert advice and an enormous breadth of advanced technologies. Our scientists use our skills for the specific product development for your schizophrenia research, including but not limited to:
Diuretics | ACE | Calcium Channel Blocker | GABAergic | DISC1 |
NMDA | GAD67 | HER4 | COMT | AMPA |
For more detailed information, please directly sent us an inquiry. We look forward to collaborating with you!
Reference
- Keefe, R. S.; Harvey, P. D. Cognitive impairment in schizophrenia. Novel antischizophrenia treatments. 2012,11-37.
- NeuroMab™ Anti-F-Spondin/SPON1 Antibody, Clone N24875P (CBP11839) (Cat#: NRZP-0822-ZP4740)
- NeuroMab™ Anti-Alpha Synuclein Antibody(NRP-0422-P614) (Cat#: NRP-0422-P614)
- NeuroMab™ Anti-TREM2 Antibody(NRP-0422-P792) (Cat#: NRP-0422-P792)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1686) (Cat#: NRP-0422-P1686)
- NeuroMab™ Anti-Amyloid Beta 1-15 Antibody(NRP-0422-P867) (Cat#: NRP-0422-P867)
- NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody(NRZP-1022-ZP3503) (Cat#: NRZP-1022-ZP3503)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1760) (Cat#: NRP-0422-P1760)
- NeuroMab™ Anti-CD32b Antibody(NRP-0422-P1803) (Cat#: NRP-0422-P1803)
- NeuroMab™ Anti-TNFα BBB Shuttle Antibody(NRZP-1022-ZP4105) (Cat#: NRZP-1022-ZP4105)
- NeuroMab™ Anti-EPHB2 Antibody(NRP-0422-P1220) (Cat#: NRP-0422-P1220)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- Rat Muller Cell (Cat#: NCL2110P040)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- iNeu™ Microglia (Cat#: NCL-7P018)
- Rat Glioma Cell Line C6 (Cat#: NCL2110P346)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Human Dental Pulp Stem Cells (Cat#: NRZP-1122-ZP113)
- Green Fluorescent Tau SH-SY5Y cell Line (Cat#: NCL2110P219)
- iNeu™ Human Midbrain Dopaminergic Neurons (Cat#: NCL-21P6-003)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- pAAV-syn-jGCaMP8m-WPRE (Cat#: NTA-2106-P062)
- rAAV-CAG-DIO-G-Flamp1 (Cat#: NRZP-0722-ZP719)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- rAAV-E-SARE-Cre-ERT2-PEST-WPRE-hGH polyA (Cat#: NTA-2010-TT342)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- Dextran, NHS Activated, 40 kDa (Cat#: NRZP-0722-ZP124)
- Dextran, Cy5 Labeled, 2000 kDa (Cat#: NRZP-0722-ZP22)
- AAV2/2Retro-CAG-DIO-EGFP-2A-TetTox-pA [Neural Tracing] (Cat#: NTA-2012-ZP303)
- pAAV-syn-jGCaMP8f-WPRE (Cat#: NTA-2106-P061)
- pAAV-EF1a-DIO-EGFP-WPRE (Cat#: NTA-2012AD-P285)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)